comparemela.com

Novartis Singapore Pharmaceutical Manufacturing News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Lipids Market is Probable to Influence the Value of USD 23,313 48 Million by 2030, Size, Share, Trends, Business Growth, Challenges and Competitive Outlook

Biontech Acquires Novartis GMP Manufacturing Facility in Singapore

With an aim to expand its business in Asia, Biontech has acquired one of Novartis’ GMP-certified manufacturing facilities in Singapore. With this move, the company intends to establish its first mrna facility in the country.

BioNTech aims to create more than 100 jobs in Singapore by 2024 at new APAC HQ

Also an mRNA manufacturing facility, it will see new roles across functions such as HR, operations, engineering, quality, finance, and supply chain management, with recruiting starting immediately for first positions.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.